ArticleBlood advances2023
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS.
Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Guideline
- Monitoring relapse in post-transplant acute myeloid leukemia requires integrated assessment, with flow cytometry showing the highest efficacy.Haematologica · 2026Article
- Mixed T-cell chimerism at 3 months predicts late relapse in acute myeloid leukemia after allogeneic stem cell transplantation.Scientific reports · 2026Article
- Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.Bone marrow transplantation · 2026Article
- Intensive Induction in AML in the Era of Venetoclax: A Standing Count for "7 + 3"?American journal of hematology · 2026Article
- Digital Surveillance After Allogeneic Hematopoietic Stem Cell Transplantation Guides Therapeutic Interventions to Reduce Non-Relapse Mortality.European journal of haematology · 2026Article
- Therapy of high-risk myelodysplastic syndromes.Bone marrow transplantation · 2026Review
- Review
- Landscape of Measurable Residual Disease in Acute Myeloid Leukemia: From Molecular Detection to Clinical Practice.Medical sciences (Basel, Switzerland) · 2026Review
- When remission alone might be good enough.Blood advances · 2026Article
- Interpreting MRD and Chimerism After Allogeneic Transplantation for Acute Leukemia.Mediterranean journal of hematology and infectious diseases · 2026Article
- Chimerism practices across Canadian transplant centres: review of current standards and variations.Frontiers in transplantation · 2026Review
- Post-Transplant Relapse in Acute Leukemia: Comparative Value of MRD and Chimerism.Mediterranean journal of hematology and infectious diseases · 2026Article
- Prognostic value of post-transplantation measurable residual disease in patients with myelodysplastic syndrome: A prospective cohort study.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old.Blood · 2025Review
- Donor lymphocyte infusions after HLA-identical hematopoietic stem cell transplantation with post-transplant cyclophosphamide in acute myeloid leukemia patients.Bone marrow transplantation · 2025Article
- Combination of disease burden before allogeneic transplantation and early post-transplant minimal residual disease predicts survival in patients with acute myeloid leukemia.Annals of hematology · 2025Article
- Impact of TP53 alteration on allogeneic hematopoietic cell transplantation outcomes for myelodysplastic syndromes.Bone marrow transplantation · 2025Article
- Exploiting HLA-DR mismatches for CAR therapy in acute myeloid leukemia.Nature cancer · 2025Article
- Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease.Bone marrow transplantation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 12 institutions in 2 countries.
Funding
Abstract
Allogeneic stem-cell transplant allows for the delivery of curative graft-versus-leukemia (GVL) in patients with acute myeloid leukemia/myelodysplasia (AML/MDS). Surveillance of T-cell chimerism, measurable residual disease (MRD) and blast HLA-DR expression may inform whether GVL effectiveness is reduced. We report here the prognostic impact of these biomarkers in patients allografted for AML/MDS. One hundred eighty-seven patients from FIGARO, a randomized trial of reduced-intensity conditioning regimens in AML/MDS, were alive and relapse-free at the first MRD time-point and provided monitoring samples for flow cytometric MRD and T-cell chimerism, requested to month+12. Twenty-nine (15.5%) patients had at least 1 MRD-positive result posttransplant. MRD-positivity was associated with reduced overall survival (OS) (hazard ratio [HR], 2.18; P = .0028) as a time-varying Cox variable and remained significant irrespective of pretransplant MRD status in multivariate analyses (P < .001). Ninety-four patients had sequential MRD with T-cell chimerism results at months+3/+6. Patients with full donor T-cell chimerism (FDTC) had an improved OS as compared with patients with mixed donor T-cell chimerism (MDTC) (adjusted HR=0.4; P = .0019). In patients with MDTC (month+3 or +6), MRD-positivity was associated with a decreased 2-year OS (34.3%) vs MRD-negativity (71.4%) (P = .001). In contrast, in the group with FDTC, MRD was infrequent and did not affect the outcome. Among patients with posttransplant MRD-positivity, decreased HLA-DR expression on blasts significantly reduced OS, supporting this as a mechanism for GVL escape. In conclusion, posttransplant MRD is an important predictor of the outcome in patients allografted for AML/MDS and is most informative when combined with T-cell chimerism results, underlining the importance of a GVL effect in AML/MDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.